AssociationBetween BRAF V 600 EMutationand MortalityinPatientsWithPapillaryThyroidCancer

Mingzhao Xing, MD, PhD Ali S. Alzahrani, MD Kathryn A. Carson, ScM David Viola, MD Rossella Elisei, MD Bela Bendlova, PhD Linwah Yip, MD Caterina Mian, MD Federica Vianello, MD R. Michael Tuttle, MD Eyal Robenshtok, MD James A. Fagin, MD Efisio Puxeddu, MD, PhD Laura Fugazzola, MD Agnieszka Czarniecka, MD Barbara Jarzab, MD, PhD Christine J. O’Neill, MBBS(Hons), MS Mark S. Sywak, MD Alfred K. Lam, MD, PhD Garcilaso Riesco-Eizaguirre, MD, PhD Pilar Santisteban, PhD Hirotaka Nakayama, MD Ralph P. Tufano, MD Sara I. Pai, M.D, PhD Martha A. Zeiger, MD William H. Westra, MD Douglas P. Clark, MD Roderick Clifton-Bligh, PhD David Sidransky, MD Paul W. Ladenson, MD Vlasta Sykorova, PhD

[1]  A. Pinchera,et al.  BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  Rebeccah L. Brown,et al.  Thyroid Cancer: Burden of Illness and Management of Disease , 2011, Journal of Cancer.

[3]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[4]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[5]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[6]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[7]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[8]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[9]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[10]  C. Nucera,et al.  BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. , 2011, Cancer research.

[11]  M. Nikiforova,et al.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. , 2009, Surgery.

[12]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[13]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[14]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[15]  P. Hou,et al.  The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells , 2012, Cell cycle.

[16]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[17]  M. Xing,et al.  Prognostic utility of BRAF mutation in papillary thyroid cancer , 2010, Molecular and Cellular Endocrinology.

[18]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[19]  Dagmara Rusinek,et al.  Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. , 2010, Endokrynologia Polska.

[20]  P. Ladenson,et al.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Hou,et al.  Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. , 2011, Endocrine-related cancer.

[22]  R. Kodet,et al.  BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic , 2010, Journal of endocrinological investigation.

[23]  N. Wada,et al.  Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. , 2007, Anticancer research.

[24]  A. Toniato,et al.  BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience , 2011, Clinical chemistry and laboratory medicine.

[25]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[26]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[27]  Y. Youn,et al.  The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer , 2012, Cancer.

[28]  Shinichi Suzuki,et al.  BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.

[29]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[30]  S Lemeshow,et al.  Confidence interval estimation of interaction. , 1992, Epidemiology.

[31]  Robert A. Smith,et al.  Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. , 2011, Human pathology.

[32]  A. Chou,et al.  BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. , 2010, Surgery.

[33]  A. Abdel‐Mageed,et al.  BRAF mutation in papillary thyroid carcinoma. , 2012, International journal of clinical and experimental medicine.